Our UHN programs and services are among the most advanced in the world. We have grouped our physicians, staff, services and resources into 10 medical programs to meet the needs of our patients and help us make the most of our resources.
University Health Network is a health care and medical research organization in Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international source for discovery, education and patient care.
Our 10 medical programs are spread across eight hospital sites – Princess Margaret, Toronto General, Toronto Rehab’s five sites, Toronto Western – as well as our education programs through the Michener Institute of Education at UHN. Learn more about the services, programs and amenities offered at each location.
Maps & Directions
Find out how to get to and around our nine locations — floor plans, parking, public transit, accessibility services, and shuttle information.
Ways You Can Help
Being touched by illness affects us in different ways. Many people want to give back to the community and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
The Newsroom is the source for media looking for information about UHN or trying to connect with one of our experts for an interview. It’s also the place to find UHN media policies and catch up on our news stories, videos, media releases, podcasts and more.
Dr. Vuk Stambolic and his research team have discovered a function of the tumor suppressor gene PTEN that helps explain why certain promising therapies fail in many cancer patients. (Photo: UHN)
Toronto (July 26, 2013) – Scientists at the Princess Margaret Cancer Centre have discovered a function of the tumor suppressor gene PTEN that helps explain why certain promising therapies fail in many cancer patients, a finding that could aid in delivering tailored, personalized cancer medicine based on an individual's genetics.
The research, published online today in Science, "increases understanding of the molecular mechanisms of action of PTEN, which is known to be defective in as many as half of all advanced cancers" says principal investigator Vuk Stambolic, Senior Scientist at the Princess Margaret Cancer Centre. Dr. Stambolic, a specialist in cell signalling, is also an Associate Professor in the Department of Medical Biophysics, University of Toronto.
In the lab, working with cell and animal models of cancer, the research team discovered what happens when the protein product of PTEN is lost or deregulated. Dr. Stambolic says: "We realized that the PTEN nuclear function links this tumor suppressor to the response to conventional cancer treatments, such as chemotherapy or radiation. This new knowledge, combined with our prior understanding of PTEN, provided immediate clues for individualizing therapy for patients with PTEN-deficient tumors."
Medical oncologist Lillian Siu, who leads numerous clinical trials at Princess Margaret, but was not directly involved in this research, says: "For clinicians, this is a significant finding that could help guide treatment decisions, especially considering that we can already test for PTEN deficiency by molecularly analyzing biopsied tissue, providing a biomarker for implementation of combined therapies that may be most effective."
For Dr. Stambolic, the discovery builds on his earlier research (Cell, 1998) which helped explain how PTEN loss promotes cell survival, another key feature of cancerous cells. "We now realize that the PTEN story was only half-told in 1998," says Dr. Stambolic. "The new findings, in conjunction with advances in molecular profiling and access to drugs already available or being tested in clinical development, present a tangible scenario to tailor treatment."
The research was funded by the Canadian Cancer Society, the Canadian Institutes of Health Research, the Ontario Ministry of Health and Long-term Care and The Princess Margaret Cancer Foundation.
The Princess Margaret Cancer Centre has achieved an international reputation as a global leader in the fight against cancer and delivering personalized cancer medicine. The Princess Margaret, one of the top five international cancer research centres, is a member of the University Health Network, which also includes Toronto General Hospital, Toronto Western Hospital and Toronto Rehabilitation Institute. All are research hospitals affiliated with the University of Toronto. For more information, go to www.theprincessmargaret.ca.
Phone: 416 340 4636